U.S. Department of Energy

Caritas St. Elizabeth's Medical Center of Boston, Inc.

Medivation, Inc.

Selena Pharmaceuticals, Inc.

Zapolsky, Maxim Eduardovich

Nikolai Serafimovich Zefirov

Sergei O Bachurin

Andrei Z Afanasiev

Elizaveta E Bukatina

Irina V Grigorieva

Svetlana V Afanasieva

Marina A Jurovskaya

Gregory F Oxenkrug

Sergey O Bachurin

Mstislav Igorevich Lavrov

Sergei E Tkachenko

Vladimir V Grigoriev

Vladimir Alexandrovich Palyulin

Valery P Chetverikov

Larisa Godvigovna Tomilova

Vladimir Vasilievich Afanasiev

Dmitry Yurievich Zalepugin

Victor Stanislavovich Polyakov

Vladmir V Grigoriev

Nataliya Alexandrovna Tilkunova

A continuous method of producing propylenecarbonate includes carboxylation of propylene oxide with carbon dioxide in presence of phthalocyanine catalyst on an inert carrier, using as the phthalocyanine catalyst at least one catalyst selected from the group consisting of not-substituted, methyl, ethyl, butyl, and tret butyl-substituted phthalocyanines of metals, including those containing counterions, and using as the carrier a hydrophobic carrier.

Continuous wasteless ecologically safe technology of propylenecarbonate production in presence of phthalocyanine catalysts

Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): wherein Ris Me, Et or PhCH; Ris H, PhCHor 6-Me-3-Py-(CH); and Ris H, Me or Br. The solid line accompanied by the dotted line i.e. represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.

Agents for treating neurodegenerative disorders

Compositions comprising 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivatives thereof for the treatment of depression are disclosed.

5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivates thereof

Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I):

Agent for treating neurodegenerative disorders

Growing community of inventors

Moscow, Russia

Nikolai Serafimovich Zefirov